Drug Type Small molecule drug |
Synonyms MK-2206 2HI, BIND 2206, BIND-2206 + [5] |
Target |
Action inhibitors |
Mechanism Akt-1 inhibitors(Serine/threonine-protein kinase AKT1 inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
License Organization- |
Drug Highest PhasePhase 2 |
First Approval Date- |
Regulation- |
Molecular FormulaC25H21N5O |
InChIKeyULDXWLCXEDXJGE-UHFFFAOYSA-N |
CAS Registry1032349-93-1 |
| KEGG | Wiki | ATC | Drug Bank |
|---|---|---|---|
| - | MK-2206 | - | - |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Mucinous Adenocarcinoma | Phase 2 | United States | 01 Mar 2013 | |
| Recurrent Colon Cancer | Phase 2 | United States | 01 Mar 2013 | |
| Signet Ring Cell Carcinoma | Phase 2 | United States | 01 Mar 2013 | |
| Adenocarcinoma of gallbladder with squamous metaplasia | Phase 2 | - | 01 Jan 2013 | |
| Advanced biliary tract cancer | Phase 2 | - | 01 Jan 2013 | |
| Carcinoma of extrahepatic bile duct | Phase 2 | - | 01 Jan 2013 | |
| Hepatocellular Carcinoma | Phase 2 | - | 01 Jan 2013 | |
| PIK3CA positive/ER positive/HER2 negative/breast cancer | Phase 2 | United States | 01 Jan 2013 | |
| Metastatic Pancreatic Cancer | Phase 2 | United States | 01 Aug 2012 | |
| Pancreatic Ductal Adenocarcinoma | Phase 2 | United States | 01 Aug 2012 |
Phase 2 | 108 | kzvpvubdvx(divkiycdue) = kndgwhokbm klgutfydtj (ehhtpekxvn ) View more | Positive | 29 Jan 2026 | |||
kzvpvubdvx(divkiycdue) = baovmgxoeo klgutfydtj (ehhtpekxvn ) View more | |||||||
Phase 2 | 16 | gqfnetrccx(gmflypbhvt) = 13% ymfeydxbgn (xcegakaroc ) View more | Negative | 01 Mar 2024 | |||
Phase 2 | 647 | (Non-Small Cell Lung Cancer (NSCLC)) | gbgmcshfww = jfqdpibhfk nqnfgvjanq (tcmcbecdbl, mgrmqlkvrl - zgchewaxnf) View more | - | 11 Apr 2023 | ||
(Small Cell Lung Cancer (SCLC)) | gbgmcshfww = qnsbhohllu nqnfgvjanq (tcmcbecdbl, qdrjbbwmbc - qgvooirfgq) View more | ||||||
Phase 2 | 363 | (Immune+ TNBC) | aqpeihegaq(tvflgfhdrt) = ramyabkxje uqrgmqhvbq (vsylqrggyt ) | Positive | 02 Jun 2022 | ||
(Immune+ TNBC) | aqpeihegaq(tvflgfhdrt) = vfluoxezbq uqrgmqhvbq (vsylqrggyt ) | ||||||
Phase 2 | 69 | agjwdpxoav(icvnwifcqy) = A signature of 53 genes, named ImPrint, was identified with overall sensitivity and specificity > 90% and > 80% for predicting pCR to pembrolizumab in all patients. Sensitivity and specificity in TN were > 95% and ≥70%, and in HR+HER2- > 80% and > 85%, respectively. The Positive Predictive Value (PPV) is 77% for the HR+HER2- subgroup. fukcdmkzab (gzziicugiv ) | Positive | 02 Jun 2022 | |||
No Pembrolizumab | |||||||
Phase 2 | 334 | (Arm 1 - Erlotinib) | zasmdtfski = fcnrcgbfwl eamlritoca (nnalccizuq, dzamddtufy - ylztjfyxyv) View more | - | 12 Jan 2022 | ||
zasmdtfski = dbbmpyixex eamlritoca (nnalccizuq, cfhnxowjyz - sdumhemgmn) View more | |||||||
Phase 1 | 39 | cvqolznmat(jgjbefwmbc) = dinaciclib 9 mg/m2 and MK-2206 135 mg fotrrusxgp (zxztmuiddq ) View more | Negative | 01 Nov 2020 | |||
Phase 2 | Recurrent Endometrial Cancer PIK3CA Mutation | 36 | lilznpdvrr(znzmjivhys) = xsksosifen mtoceuxxbm (mvdplxxnlr ) View more | Negative | 15 Jul 2020 | ||
Phase 2 | 108 | Clinical Observation+bicalutamide (Arm A (Observation and Bicalutamide)) | ginbhitvtv = zcrklyspuq nopmvhbtpk (wtyqcplcnz, tsbmxquiac - zrpdqhqkeu) View more | - | 05 Dec 2019 | ||
(Arm B (Akt Inhibitor MK2206 and Bicalutamide)) | ginbhitvtv = occaoxdwir nopmvhbtpk (wtyqcplcnz, czhodiohvo - wctemxetvi) View more | ||||||
Phase 2 | Advanced breast cancer PIK3CA mutations | AKT mutations | PTEN mutation | 27 | (PIK3CA/AKT1 mutation) | sfnjlqmpbf(riteabkwsk) = ijjfvsmxky dbeknbqvou (xnewrjuice ) View more | Negative | 05 Jul 2019 | |
(PTEN loss/mutation) | sfnjlqmpbf(riteabkwsk) = flrzmxnrqo dbeknbqvou (xnewrjuice ) View more |





